Response to: 'Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series' by Narváez

Ann Rheum Dis. 2019 Nov;78(11):e124. doi: 10.1136/annrheumdis-2018-214477. Epub 2018 Oct 23.

Authors

Dinesh Khanna¹, Angelika Jahreis², Celia J F Lin²

Affiliations

¹ Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA khannad@med.umich.edu.
² Product Development, Genentech, Inc, South San Francisco, California, USA.

PMID: 30352886
DOI: 10.1136/annrheumdis-2018-214477

No abstract available

Keywords: CLINICAL TRIAL; disease activity; pulmonary fibrosis; systemic sclerosis; tocilizumab.

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Humans
Lung Diseases, Interstitial*
Scleroderma, Systemic*

Substances

Antibodies, Monoclonal, Humanized
tocilizumab